ArticleBritish journal of haematology2025

Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003).

Paolo Strati et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.